- Home
- ADV vs SVRA Comparison
ADV vs SVRA Comparison
Compare ADV & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- SVRA
- Stock Information
- Founded
- ADV 1987
- SVRA 2007
- Country
- ADV United States
- SVRA United States
- Employees
- ADV N/A
- SVRA N/A
- Industry
- ADV Business Services
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- SVRA Health Care
- Exchange
- ADV Nasdaq
- SVRA Nasdaq
- Market Cap
- ADV 586.7M
- SVRA 527.2M
- IPO Year
- ADV N/A
- SVRA N/A
- Fundamental
- Price
- ADV $1.85
- SVRA $3.28
- Analyst Decision
- ADV Strong Buy
- SVRA Buy
- Analyst Count
- ADV 1
- SVRA 7
- Target Price
- ADV $2.50
- SVRA $5.57
- AVG Volume (30 Days)
- ADV 972.5K
- SVRA 1.4M
- Earning Date
- ADV 08-07-2025
- SVRA 08-13-2025
- Dividend Yield
- ADV N/A
- SVRA N/A
- EPS Growth
- ADV N/A
- SVRA N/A
- EPS
- ADV N/A
- SVRA N/A
- Revenue
- ADV $3,527,054,000.00
- SVRA N/A
- Revenue This Year
- ADV N/A
- SVRA N/A
- Revenue Next Year
- ADV N/A
- SVRA N/A
- P/E Ratio
- ADV N/A
- SVRA N/A
- Revenue Growth
- ADV N/A
- SVRA N/A
- 52 Week Low
- ADV $1.04
- SVRA $1.89
- 52 Week High
- ADV $4.10
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- ADV 59.79
- SVRA 72.04
- Support Level
- ADV $1.76
- SVRA $2.92
- Resistance Level
- ADV $1.90
- SVRA $3.28
- Average True Range (ATR)
- ADV 0.14
- SVRA 0.21
- MACD
- ADV 0.00
- SVRA 0.02
- Stochastic Oscillator
- ADV 65.00
- SVRA 89.47
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.